Drugs Exp Clin Res. 1996;22(3-5):115-22.
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for
Susak YM, Zemskov VS, Yaremchuk OY, Kravchenco OB, Yatsyk IM, Korsh OB.
Department of General Surgery, Ukrainian State Medical University, Kiev, Ukraine.
Ninety six colorectal carcinoma patients were included in a randomised study, 48
were treated with Ukrain monotherapy (15 with metastatic and 33 with
nonmetastatic colorectal carcinoma) and 48 with 5-fluorouracil (5-FU) and X-ray
therapy (the same randomised groups). The results of therapy including clinical,
haematological, immunological and biochemical parameters show that Ukrain has
favourable properties in the treatment of colon and rectal cancer as a
monotherapy because of its malignotoxic and immunomodulating action. Objective
response rate in the group of metastatic colorectal cancer treated by Ukrain was
40%. There was no registered tumour regression in the group treated by 5-FU.
Operability is strongly facilitated by pretreatment with Ukrain. The survival
rate (up to 21 months) in the Ukrain-treated patients with nonmetastatic
colorectal cancer was 78.6% and 33.3% in a corresponding control group. Ukrain is
a new effective drug in the therapy of colorectal cancer. It can be useful both
for the therapy of metastatic colorectal cancer and for neoadjuvant therapy of
nonmetastatic colorectal cancer.